BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 20811628)

  • 21. Contrasting Pattern of Chronic Inflammatory Bowel Disease in Primary and Autoimmune Sclerosing Cholangitis.
    Bjarnason I; Hayee B; Pavlidis P; Kvasnovsky C; Scalori A; Sisson G; Charlesworth A; Shaikh H; Bjornsson E; Heneghan MA
    EBioMedicine; 2015 Oct; 2(10):1523-7. PubMed ID: 26629548
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of ulcerative colitis on the long-term outcome of patients with primary sclerosing cholangitis.
    Navaneethan U; Venkatesh PG; Lashner BA; Shen B; Kiran RP
    Aliment Pharmacol Ther; 2012 May; 35(9):1045-53. PubMed ID: 22428605
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Course of Ulcerative Colitis After Liver Transplantation in Patients with Concomitant Primary Sclerosing Cholangitis and Ulcerative Colitis.
    Fattahi MR; Malek-Hosseini SA; Sivandzadeh GR; Safarpour AR; Bagheri Lankarani K; Taghavi AR; Ejtehadi F
    Inflamm Bowel Dis; 2017 Jul; 23(7):1160-1167. PubMed ID: 28520586
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease.
    Boonstra K; van Erpecum KJ; van Nieuwkerk KM; Drenth JP; Poen AC; Witteman BJ; Tuynman HA; Beuers U; Ponsioen CY
    Inflamm Bowel Dis; 2012 Dec; 18(12):2270-6. PubMed ID: 22407885
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Three ulcerative colitis susceptibility loci are associated with primary sclerosing cholangitis and indicate a role for IL2, REL, and CARD9.
    Janse M; Lamberts LE; Franke L; Raychaudhuri S; Ellinghaus E; Muri Boberg K; Melum E; Folseraas T; Schrumpf E; Bergquist A; Björnsson E; Fu J; Jan Westra H; Groen HJ; Fehrmann RS; Smolonska J; van den Berg LH; Ophoff RA; Porte RJ; Weismüller TJ; Wedemeyer J; Schramm C; Sterneck M; Günther R; Braun F; Vermeire S; Henckaerts L; Wijmenga C; Ponsioen CY; Schreiber S; Karlsen TH; Franke A; Weersma RK
    Hepatology; 2011 Jun; 53(6):1977-85. PubMed ID: 21425313
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis Frequently Have Subclinical Inflammation in the Proximal Colon.
    Krugliak Cleveland N; Rubin DT; Hart J; Weber CR; Meckel K; Tran AL; Aelvoet AS; Pan I; Gonsalves A; Gaetano JN; Williams KM; Wroblewski K; Jabri B; Pekow J
    Clin Gastroenterol Hepatol; 2018 Jan; 16(1):68-74. PubMed ID: 28756053
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of matrix metalloproteinase-1 and -3 promoter polymorphisms with clinical subsets of Norwegian primary sclerosing cholangitis patients.
    Wiencke K; Louka AS; Spurkland A; Vatn M; Schrumpf E; Boberg KM;
    J Hepatol; 2004 Aug; 41(2):209-14. PubMed ID: 15288468
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis.
    Vesterhus M; Holm A; Hov JR; Nygård S; Schrumpf E; Melum E; Thorbjørnsen LW; Paulsen V; Lundin K; Dale I; Gilja OH; Zweers SJLB; Vatn M; Schaap FG; Jansen PLM; Ueland T; Røsjø H; Moum B; Ponsioen CY; Boberg KM; Färkkilä M; Karlsen TH; Lund-Johansen F
    J Hepatol; 2017 Jun; 66(6):1214-1222. PubMed ID: 28161472
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls.
    Kummen M; Holm K; Anmarkrud JA; Nygård S; Vesterhus M; Høivik ML; Trøseid M; Marschall HU; Schrumpf E; Moum B; Røsjø H; Aukrust P; Karlsen TH; Hov JR
    Gut; 2017 Apr; 66(4):611-619. PubMed ID: 26887816
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential.
    Broomé U; Löfberg R; Veress B; Eriksson LS
    Hepatology; 1995 Nov; 22(5):1404-8. PubMed ID: 7590655
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TGR5 in the Cholangiociliopathies.
    Masyuk TV; Masyuk AI; LaRusso NF
    Dig Dis; 2015; 33(3):420-5. PubMed ID: 26045278
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Unique Inflammatory Bowel Disease Phenotype of Pediatric Primary Sclerosing Cholangitis: A Single-Center Study.
    Shiau H; Ihekweazu FD; Amin M; Fofanova T; Miloh T; Kellermayer R
    J Pediatr Gastroenterol Nutr; 2017 Oct; 65(4):404-409. PubMed ID: 28141677
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Farnesoid X receptor expression is decreased in colonic mucosa of patients with primary sclerosing cholangitis and colitis-associated neoplasia.
    Torres J; Bao X; Iuga AC; Chen A; Harpaz N; Ullman T; Cohen BL; Pineton de Chambrun G; Asciutti S; Odin JA; Sachar DB; Gaskins HR; Setchell K; Colombel JF; Itzkowitz SH
    Inflamm Bowel Dis; 2013 Feb; 19(2):275-82. PubMed ID: 23348121
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gut Microbiome of Children and Adolescents With Primary Sclerosing Cholangitis in Association With Ulcerative Colitis.
    Cortez RV; Moreira LN; Padilha M; Bibas MD; Toma RK; Porta G; Taddei CR
    Front Immunol; 2020; 11():598152. PubMed ID: 33613519
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis.
    Jendrek ST; Gotthardt D; Nitzsche T; Widmann L; Korf T; Michaels MA; Weiss KH; Liaskou E; Vesterhus M; Karlsen TH; Mindorf S; Schemmer P; Bär F; Teegen B; Schröder T; Ehlers M; Hammers CM; Komorowski L; Lehnert H; Fellermann K; Derer S; Hov JR; Sina C
    Gut; 2017 Jan; 66(1):137-144. PubMed ID: 27406039
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fine mapping and replication of genetic risk loci in primary sclerosing cholangitis.
    Srivastava B; Mells GF; Cordell HJ; Muriithi A; Brown M; Ellinghaus E; Franke A; ; Karlsen TH; Sandford RN; Alexander GJ; Chapman RW; Rushbrook SM; Melum E
    Scand J Gastroenterol; 2012 Jul; 47(7):820-6. PubMed ID: 22554193
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CC-type chemokine receptor 5-Delta32 mutation protects against primary sclerosing cholangitis.
    Henckaerts L; Fevery J; Van Steenbergen W; Verslype C; Yap P; Nevens F; Roskams T; Libbrecht L; Rutgeerts P; Vermeire S
    Inflamm Bowel Dis; 2006 Apr; 12(4):272-7. PubMed ID: 16633049
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Duration and severity of primary sclerosing cholangitis is not associated with risk of neoplastic changes in the colon in patients with ulcerative colitis.
    Navaneethan U; Kochhar G; Venkatesh PG; Lewis B; Lashner BA; Remzi FH; Shen B; Kiran RP
    Gastrointest Endosc; 2012 May; 75(5):1045-1054.e1. PubMed ID: 22405258
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A population-based cohort study of pregnancy outcomes among women with primary sclerosing cholangitis.
    Ludvigsson JF; Bergquist A; Ajne G; Kane S; Ekbom A; Stephansson O
    Clin Gastroenterol Hepatol; 2014 Jan; 12(1):95-100.e1. PubMed ID: 23891928
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Distinct gut microbiota profiles in patients with primary sclerosing cholangitis and ulcerative colitis.
    Bajer L; Kverka M; Kostovcik M; Macinga P; Dvorak J; Stehlikova Z; Brezina J; Wohl P; Spicak J; Drastich P
    World J Gastroenterol; 2017 Jul; 23(25):4548-4558. PubMed ID: 28740343
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.